Clinical Trial Update: Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of erlotinib and docetaxel as first-line therapy for selected non-small cell lung cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Meir Medical Center | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED